Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kate Rawson

Kate Rawson is a Contributing Editor at Prevision Policy. She was a Senior Editor at The RPM Report and reporter and editor at The Pink Sheet where she covered drug regulation and reimbursement issues. During her ten-year tenure at FDC Reports, she helped launch The Pink Sheet DAILY, and also served as Managing Editor of The Rose Sheet, which covers regulatory and business news of the cosmetics industry.

Latest From Kate Rawson

NDAs, BLAs To Start Getting KASA Quality Risk Assessments After Successful Pilot With ANDAs

Internal review system reduces US FDA’s administrative work for OPQ risk assessments; agency’s standards will not change, and sponsors will not need to modify applications. Advisory committee endorses expansion, which will roll out to different application types over several years.

Quality Risk Management

Expanded Access Cost Distribution: FDA Clarifies New Rules For Charging Patients

Revised draft guidance makes clear that sponsors may charge all patients a flat administrative fee to cover ‘startup’ costs, regardless of when they join.

Reimbursement Regulation

US FDA Advisory Committee ‘Update’ May Result In More Meetings – And More Re-Reviews

Commissioner Robert Califf’s comments offer further context for FDA’s unprecedented decision to reconvene an advisory committee for a second review of Amylyx’ AMX0035 for ALS.

Advisory Committees Review Pathway

‘I’m Still Here’: Woodcock’s Swan Song At US FDA Looking Like A Longer-Term Job

Janet Woodcock’s imminent departure from FDA has been predicted often during her tenure. Her latest project may keep her there longer than even she thought possible.

FDA Leadership

‘I’m Still Here’: Janet Woodcock’s Swan Song At US FDA Looking Like A Longer-Term Job

Janet Woodcock’s imminent departure from the agency has been predicted often during her tenure. Her latest project may keep her there longer than even she thought possible.

FDA Leadership

Accelerated Approvals Convert Much Faster If Confirmatory Trial Already Underway, FDA Cancer Data Shows

Oncology Center of Excellence’s ‘Project Confirm’ finds that if a confirmatory trial is ongoing at the time of accelerated approval, conversion to regular approval takes an average of three years versus 4.9 years if the trial starts after AA.

Cancer Review Pathway
See All
UsernamePublicRestriction

Register